Daily2d
Study finds certain MS therapies may not slow disability progression
In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before ...
WebMD25d
FDA Approves First Injectable for Relapsing and Progressive MS
The FDA has approved a new injectable form of the multiple sclerosis drug ocrelizumab for use in adults with relapsing and progressive forms of the disease. Multiple sclerosis occurs when the body ...
BioSpace13d
Sanofi, Denali Abandon Mid-Stage Multiple Sclerosis Study on Disappointing Data
Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic ...
Medpage Today on MSN16d
Some Cancers Occur More Frequently in Multiple Sclerosis Patients
Some cancers occurred more frequently in people with multiple sclerosis (MS) than in others, a retrospective study in France ...
Medical Xpress29d
FDA approves injectable Ocrevus Zunovo for relapsing, progressive multiple sclerosis
The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with ...
BBC3mon
NHS rolls out 'speedy' MS injection
The medicine, called ocrelizumab, is normally given as an infusion through a vein - a process that can take up to four hours in hospital. The new way to give the drug will help free up patients ...
Pharmac needs to factor in indirect costs into funding decisions - health economists
An overhaul of the way Pharmac decides to fund drugs for people with chronic long term diseases is needed, say health economists, who are asking the agency to consider the wider societal burden of the ...
Medscape25d
Time to Revisit the Standard Treatment Approach in Kids With MS?
Hacohen reported on a UK cohort of children with MS treated with ocrelizumab, with 66 patients having more than 12 months of follow-up. Of these, only four patients had relapses, and there was no ...
News Medical1mon
Research questions effectiveness of MS medications in slowing disability progression
About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white ...
WebMD3y
Multiple Sclerosis Resource Center
FDA Approves First Injectable for Relapsing and Progressive MSThe FDA has approved a new injectable form of the multiple sclerosis drug ocrelizumab for use in adults with relapsing and progressive ...
Science Daily1mon
Study finds certain MS therapies may not slow disability progression
About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white ...
Medical Xpress1mon
Study finds certain multiple sclerosis therapies may not slow disability progression
About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white ...